Literature DB >> 31075399

The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation.

Mengxue Zhang1, Bowen Wang2, Go Urabe3, Yitao Huang4, Jorge Plutzky5, K Craig Kent2, Lian-Wang Guo6.   

Abstract

BACKGROUND: Vein-graft bypass is commonly performed to overcome atherosclerosis but is limited by high failure rates, principally due to neointimal wall thickening. Recent studies reveal that endothelial-mesenchymal transition (EndoMT) is critical for vein-graft neointima formation. BETs are a family of Bromo/ExtraTerminal domains-containing epigenetic reader proteins (BRD2, BRD3, BRD4). They bind acetylated histones through their unique tandem bromodomains (BD1, BD2), facilitating transcriptional complex formation and cell-state transitions. The role for BETs, including individual BRDs and their unique BDs, is not well understood in EndoMT and neointimal formation. METHODS AND
RESULTS: Repression of BRD4 expression abrogated TGFβ1-induced EndoMT, with greater effects than BRD2 or BRD3 knockdown. An inhibitor selective for BD2 in all BETs, but not that for BD1, blocked EndoMT. Moreover, expression of a dominant-negative BRD4-specific BD2 fully abolished EndoMT. Concordantly, BRD4 knockdown repressed TGFβ1-stimulated increase of ZEB1 protein - a transcription factor integral in EndoMT. In vivo, lentiviral gene transfer of either BRD4 shRNA or dominant negative BRD4-specific BD2 mitigated neointimal development in rat jugular veins grafted to carotid arteries.
CONCLUSIONS: Our data reveal the BD2 domain of BRD4 as a determinant driving EndoMT in vitro and neointimal formation in vivo. These findings provide new insight into BET biology, while offering prospects of specific BET domain targeting as an approach to limiting neointima and extending vein graft patency.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRD4; Bromodomain-2; EndoMT; Vein graft neointima; ZEB1

Mesh:

Substances:

Year:  2019        PMID: 31075399      PMCID: PMC6561802          DOI: 10.1016/j.cellsig.2019.05.005

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  27 in total

1.  RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.

Authors:  Sarah Picaud; Christopher Wells; Ildiko Felletar; Deborah Brotherton; Sarah Martin; Pavel Savitsky; Beatriz Diez-Dacal; Martin Philpott; Chas Bountra; Hannah Lingard; Oleg Fedorov; Susanne Müller; Paul E Brennan; Stefan Knapp; Panagis Filippakopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

Review 2.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

Review 3.  Rationale and practical techniques for mouse models of early vein graft adaptations.

Authors:  Peng Yu; Binh T Nguyen; Ming Tao; Christina Campagna; C Keith Ozaki
Journal:  J Vasc Surg       Date:  2010-06-22       Impact factor: 4.268

4.  Suppression of inflammation by a synthetic histone mimic.

Authors:  Edwige Nicodeme; Kate L Jeffrey; Uwe Schaefer; Soren Beinke; Scott Dewell; Chun-Wa Chung; Rohit Chandwani; Ivan Marazzi; Paul Wilson; Hervé Coste; Julia White; Jorge Kirilovsky; Charles M Rice; Jose M Lora; Rab K Prinjha; Kevin Lee; Alexander Tarakhovsky
Journal:  Nature       Date:  2010-11-10       Impact factor: 49.962

5.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.

Authors:  Jian Shi; Yifan Wang; Lei Zeng; Yadi Wu; Jiong Deng; Qiang Zhang; Yiwei Lin; Junlin Li; Tiebang Kang; Min Tao; Elena Rusinova; Guangtao Zhang; Chi Wang; Haining Zhu; Jun Yao; Yi-Xin Zeng; B Mark Evers; Ming-Ming Zhou; Binhua P Zhou
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

6.  Established neointimal hyperplasia in vein grafts expands via TGF-beta-mediated progressive fibrosis.

Authors:  Zhihua Jiang; Ming Tao; Kerri A Omalley; Danlu Wang; C Keith Ozaki; Scott A Berceli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-17       Impact factor: 4.733

7.  BET bromodomains mediate transcriptional pause release in heart failure.

Authors:  Priti Anand; Jonathan D Brown; Charles Y Lin; Jun Qi; Rongli Zhang; Pedro Calderon Artero; M Amer Alaiti; Jace Bullard; Kareem Alazem; Kenneth B Margulies; Thomas P Cappola; Madeleine Lemieux; Jorge Plutzky; James E Bradner; Saptarsi M Haldar
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

8.  TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling.

Authors:  Brian C Cooley; Jose Nevado; Jason Mellad; Dan Yang; Cynthia St Hilaire; Alejandra Negro; Fang Fang; Guibin Chen; Hong San; Avram D Walts; Robin L Schwartzbeck; Brandi Taylor; Jan D Lanzer; Andrew Wragg; Abdalla Elagha; Leilani E Beltran; Colin Berry; Robert Feil; Renu Virmani; Elena Ladich; Jason C Kovacic; Manfred Boehm
Journal:  Sci Transl Med       Date:  2014-03-12       Impact factor: 17.956

9.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Authors:  Johannes Zuber; Junwei Shi; Eric Wang; Amy R Rappaport; Harald Herrmann; Edward A Sison; Daniel Magoon; Jun Qi; Katharina Blatt; Mark Wunderlich; Meredith J Taylor; Christopher Johns; Agustin Chicas; James C Mulloy; Scott C Kogan; Patrick Brown; Peter Valent; James E Bradner; Scott W Lowe; Christopher R Vakoc
Journal:  Nature       Date:  2011-08-03       Impact factor: 49.962

10.  Transforming growth factor-β in graft vessels: histology and immunohistochemistry.

Authors:  Shi-Min Yuan; Yan-Qing Wang; Yi Shen; Hua Jing
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more
  6 in total

Review 1.  BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.

Authors:  Patricia Cristine Borck; Lian-Wang Guo; Jorge Plutzky
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  SREBP1 regulates Lgals3 activation in response to cholesterol loading.

Authors:  Jing Li; Hongtao Shen; Gary K Owens; Lian-Wang Guo
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-18       Impact factor: 10.183

3.  A hierarchical and collaborative BRD4/CEBPD partnership governs vascular smooth muscle cell inflammation.

Authors:  Qingwei Wang; Hatice Gulcin Ozer; Bowen Wang; Mengxue Zhang; Go Urabe; Yitao Huang; K Craig Kent; Lian-Wang Guo
Journal:  Mol Ther Methods Clin Dev       Date:  2021-02-27       Impact factor: 6.698

4.  Angioplasty induces epigenomic remodeling in injured arteries.

Authors:  Mengxue Zhang; Go Urabe; Hatice Gulcin Ozer; Xiujie Xie; Amy Webb; Takuro Shirasu; Jing Li; Renzhi Han; K Craig Kent; Bowen Wang; Lian-Wang Guo
Journal:  Life Sci Alliance       Date:  2022-02-15

5.  Nullifying epigenetic writer DOT1L attenuates neointimal hyperplasia.

Authors:  Yitao Huang; Go Urabe; Mengxue Zhang; Jing Li; Hatice Gulcin Ozer; Bowen Wang; K Craig Kent; Lian-Wang Guo
Journal:  Atherosclerosis       Date:  2020-07-02       Impact factor: 5.162

6.  High stretch induces endothelial dysfunction accompanied by oxidative stress and actin remodeling in human saphenous vein endothelial cells.

Authors:  T Girão-Silva; M H Fonseca-Alaniz; J C Ribeiro-Silva; J Lee; N P Patil; L A Dallan; A B Baker; M C Harmsen; J E Krieger; A A Miyakawa
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.